NASDAQ$ANGO

AngioDynamics Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

AngioDynamics reported financial results for the first quarter of fiscal year 2023 and reaffirmed guidance.

AngioDynamics reported a 5.9% increase in net sales compared to the prior-year quarter. Med Tech net sales increased 29.6%, while Med Device net sales decreased 1.1%. The company's GAAP loss per share was $0.33, and adjusted loss per share was $0.06.

  • Net sales increased by 5.9% compared to the prior-year quarter.
  • Med Tech net sales increased by 29.6%.
  • Med Device net sales decreased by 1.1%.
  • The Company commenced the Full Market Release of the AlphaVac F18 Mechanical Thrombectomy device

Headline financials

Total Revenue

$81.5M

Previous: $77M+5.9%
EPS (adj)

-$0.06

Previous: -$0.02-200.0%
Gross Margin

51.9%

Previous: 52.1%-0.4%
Capital Expenditures

-$809K

Previous: -$1.02M+20.8%
Free Cash Flow

-$13.8M

Previous: -$7.99M-72.8%
Net Income

-$13M

Previous: -$6.97M-86.5%
Operating Income

-$13.3M

Previous: -$8.1M-64.2%
Gross Profit

$42.3M

Previous: $40.1M+5.4%
Cash & Equivalents

$24.6M

Previous: $35.5M-30.8%
Total Assets

$558M

Previous: $556M+0.3%
Stock-Based Comp

$3.02M

Previous: $2.43M+24.5%

Revenue & EPS history

AngioDynamics · Revenue · Quarterly

$81.5M

Q1 2023+5.9%vs Q1 2022
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Revenue by segment

AngioDynamics · $81.5M total across 2 segments · Q1 2023

  • Med Device
    $58.7M-1.1%
  • Med Tech
    $22.8M+29.4%

Forward guidance

Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.

Tailwinds

  • Net sales to be in the range of $342 to $348 million
  • Gross margin to be approximately 52.5% to 54.5%
  • Adjusted earnings per share in the range of $0.01 to $0.06
  • Company continues to invest in new product launches
  • Company will drive future growth

Headwinds

  • challenging and uncertain macro environment
  • persistent inflation
  • hospital staffing pressures
  • procedural pressures
  • Company recorded a net loss of $13.0 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.9%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-3.7%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+30.9%

Q2 2025

Best reaction

-26.2%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+5.0%-5.0%
Q2 2026-13.5%-25.5%-24.0%
Q1 2026+6.1%-0.2%+8.7%
Q4 2025-10.2%-9.8%-9.3%
Q3 2025+12.4%-3.6%-3.8%
Q2 2025+30.9%+32.6%+17.4%
Q1 2025-20.3%-23.1%-12.7%
Q4 2024+24.8%+21.1%+25.8%
Q3 2024+15.6%+14.6%+3.1%
Q2 2024-17.7%-20.1%-23.5%
Q1 2024-5.9%-7.2%-10.4%
Q4 2023-2.5%-3.8%-16.1%
Q3 2023-17.1%-23.3%-33.3%
Q2 2023+11.5%-1.0%-1.3%
Q1 2023-26.2%-38.0%-34.8%
Q4 2022+4.4%+6.4%+21.3%
Q3 2022+9.8%+7.2%-8.7%
Q2 2022-15.5%-15.5%-25.8%
Q1 2022+12.6%+17.8%+22.4%
Q4 2021-7.0%-8.6%-3.9%
Q3 2021+12.3%+11.1%+16.3%
Q2 2021+14.7%+14.2%+24.7%
Q1 2021+13.0%+7.8%-0.1%
Q4 2020-11.5%-11.8%-12.7%
Q3 2020-2.7%+2.3%-0.6%
Q2 2020-9.2%-11.3%-17.0%
Q1 2020-17.6%-17.6%-13.7%
Q4 2019+6.8%+6.2%-4.8%
Q3 2019-7.7%-8.2%-18.4%
Q2 2019+6.7%+6.7%+8.6%
Q1 2019-10.3%-12.9%-17.0%
Q4 2018-9.2%-7.8%-5.4%
Q3 2018+3.2%+8.9%+16.4%
Q2 2018-1.8%-0.1%+5.1%
Q1 2018-8.9%-9.1%-8.4%
Q4 2017-5.9%-3.5%+5.1%
Q3 2017+0.3%-1.3%-10.2%
Q2 2017+1.7%+3.2%-2.5%
Q1 2017-4.5%-0.1%-8.4%
Q4 2016+10.6%+14.1%+8.4%
Q3 2016-2.1%
Q2 2016-8.7%
Q1 2016-8.8%
Q4 2015-2.3%
Q3 2015-6.1%
Q2 2015-0.9%
Q1 2015+3.8%
Q4 2014-5.0%
Q3 2014-1.5%
Q2 2014+6.1%
Q1 2014+5.3%
Q4 2013+1.3%
Q3 2013-7.4%
Q2 2013-2.4%
Q1 2013-8.8%
Q4 2010-0.9%
Q4 2012+4.0%
Q3 2011-1.3%
Q3 2012-1.3%
Q2 2012-5.7%
Q2 2011-5.7%
Q1 2011+3.5%
Q4 2011+3.5%
Q1 2012+3.5%
Q3 2010+0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro